Skip to main content
Fig. 8 | Cardiovascular Diabetology

Fig. 8

From: The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin

Fig. 8

Putative mechanisms of action of EMPA against doxorubicin-induced cardiotoxicity. EMPA inhibits the activity of SGLT-2 thereby reducing intracellular glucose and sodium in cardiomyocytes, resulting in the inhibition of iROS, lipid peroxidation and NLRP3/MyD88-related pathways; the inhibition of NLRP3 and NF-kB reduces the pro-inflammatory cytokine storm in cardiomyocytes exposed to DOXO

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840